175277-18-6

Basic information

• Product Name: 4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE
• Synonyms: BUTTPARK 30\01-49;4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE;4-(TRIFLUOROMETHOXY)BENZOHYDRAZIDE;4-(Trifluoromethoxy)benzoic acid hydrazide 95%;4-(Trifluoromethoxy)benzoicacidhydrazide95%;4-(trifluoromethoxy)benzene-1-carbohydrazide;4-(Trifluoromethoxy)benzohydrazide, 4-(Trifluoromethoxy)benzenecarbohydrazide;4-Trifluoromethoxybenzhydrazide
• CAS NO: 175277-18-6
• Molecular Formula: C8H7F3N2O2
• Molecular Weight: 220.15
• Mol File: 175277-18-6.mol
• Article Data: 7

Chemical Properties

• Melting Point: 110 °C
• Appearance: /
• Density: 1.399g/cm³
• Refractive Index: 1.495
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 11.95±0.10(Predicted)
• CAS DataBase Reference: 4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE(175277-18-6)
• EPA Substance Registry System: 4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE(175277-18-6)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22
• Safety Statements: 22-36
• HazardClass: IRRITANT
• Hazardous Substances Data: 175277-18-6(Hazardous Substances Data)

Usage

General Description

4-(Trifluoromethoxy)benzoic acid hydrazide is a chemical compound with the molecular formula C8H6F3NO2. It is a derivative of benzoic acid with a trifluoromethoxy group attached to the aromatic ring. 4-(TRIFLUOROMETHOXY)BENZOIC ACID HYDRAZIDE is commonly used in organic synthesis as a reagent for the preparation of various organic compounds. It can also be used as a precursor for the synthesis of pharmaceuticals and agrochemicals. Additionally, 4-(Trifluoromethoxy)benzoic acid hydrazide has potential applications in materials science, such as in the development of advanced polymers and functional materials. Due to its versatile reactivity and unique structural features, this chemical compound is of interest to researchers in various fields of chemistry and related disciplines.

InChI:InChI=1/C8H7F3N2O2/c9-8(10,11)15-6-3-1-5(2-4-6)7(14)13-12/h1-4H,12H2,(H,13,14)

Upstream product

• 330-12-1 4-trifluoromethoxybenzoic acid 
• 36823-88-8 4-(trifluoromethoxy)benzoyl chloride 
• 780-31-4 methyl 4-(trifluoromethoxy)benzoate 

Downstream Products

• 1571031-72-5 6-methyl-2-oxo-N'-(4-(trifluoromethoxy)benzoyl)-1,2-dihydropyridine-3-carbohydrazide 
• 1609548-39-1 C₃₃H₃₅F₄N₅O₂S 
• 587-18-8 4-trifluoromethoxy-benzoic acid ethyl ester 
• 1571022-03-1 6-methyl-1-((2-(4-methylpiperazin-1-yl)pyridin-4-yl)methyl)-3-(5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one 
• 1571031-80-5 1-((2-chloropyridin-4-yl)methyl)-6-methyl-3-(5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one 
• 1571031-84-9 2-(2-((2-chloropyridin-4-yl)methoxy)-6-methylpyridin-3-yl)-5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazole 
• 1571031-76-9 6-methyl-3-(5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one 
• 1571034-75-7 C₂₆H₂₄F₃N₅O₃ 
• 1571034-81-5 5-(5-(4-(trifluoromethoxy)phenyl)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one 

Relevant articles and documents

Synthesis of benzoyl hydrazones having 4-hydroxy-3,5-dimethoxy phenyl ring, their biological activities, and molecular modeling studies on enzyme inhibition activities

Hydrazone compounds have high capacity in terms of antioxidant activity and enzyme inhibition activities such as anticholinesterase, tyrosinase, and urease. In this study, benzoyl hydrazones compounds (7a-7m) were synthesized starting from 3,5-dimethoxy-4

ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND

The present invention relates to an isoindoline compound as represented by general formula (I) and used as a CRBN regulator, and a preparation method, a pharmaceutical composition, and an application of the isoindoline compound. Specifically, a class of polysubstituted isoindoline compound provided in the present invention, as a class of CRL4CRBN E3 ubiquitin ligase regulator having a novel structure, has good anti-tumor activity and immunoregulatory activity, and can be used for preparing drugs for treating diseases associated with a CRL4CRBN E3 ubiquitin ligase.

Novel Molecular Hybrids of N-Benzylpiperidine and 1,3,4-Oxadiazole as Multitargeted Therapeutics to Treat Alzheimer's Disease

Multitargeted hybrids of N-benzylpiperidine and substituted 5-phenyl-1,3,4-oxadiazoles were designed, synthesized, and evaluated against Alzheimer's disease (AD). Tested compounds exhibited moderate to excellent inhibition against human acetylcholinesterase (hAChE), butyrylcholinesterase (hBChE), and beta-secretase-1 (hBACE-1). The potential leads 6g and 10f exhibited balanced inhibitory profiles against all the targets, with a substantial displacement of propidium iodide from the peripheral anionic site of hAChE. Hybrids 6g and 10f also elicited favorable permeation across the blood-brain barrier and were devoid of neurotoxic liability toward SH-SY5Y neuroblastoma cells. Both leads remarkably disassembled Aβ aggregation in thioflavin T-based self- and AChE-induced experiments. Compounds 6g and 10f ameliorated scopolamine-induced cognitive dysfunctions in the Y-maze test. The ex vivo studies of rat brain homogenates established the reduced AChE levels and antioxidant activity of both compounds. Compound 6g also elicited noteworthy improvement in Aβ-induced cognitive dysfunctions in the Morris water maze test with downregulation in the expression of Aβ and BACE-1 proteins corroborated by Western blot and immunohistochemical analysis. The pharmacokinetic study showed excellent oral absorption characteristics of compound 6g. The in silico molecular docking and dynamics simulation studies of lead compounds affirmed their consensual binding interactions with PAS-AChE and aspartate dyad of BACE-1.